Study of IBI3016 in People With Mild or Moderate Hypertension Patients

Inclusion Criteria: 1. Signed informed consent. 2. Males or females aged 18 to 75 years. 3 Diagnosed primary hypertension who have not been taking anti-hypertensive medication within 4 weeks prior to informed consent. 4.Mean sitting SBP ≥140 mmHg and \< 170 mmHg measured by OBPM. 5.Participants able to understand and comply with study procedures. Exclusion Criteria: 1. Known history of secondary hypertension. 2. Orthostatic hypotension. 3. Laboratory parameter assessments outside of range at screening： * Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST) \> 2× Upper Limit of Normal (ULN) * Total Bilirubin \> 1.5× ULN * International Normalized Ratio (INR) \> 2.0 * Serum Potassium \> 5 mmol/L * Estimated Glomerular Filtration Rate (eGFR) ≤ 45 mL/min/1.73m² * QTcF \> 480 ms 4. Medical condition, other than hypertension, requiring treatment with RAAS inhibitor. 5. Current or history of intolerance to ACEi and/or ARBs. 6. Acute myocardial infarction (AMI), unstable angina, percutaneous coronary intervention (PCI) , coronary artery bypass graft (CABG), ischemic or hemorrhagic stroke, transient ischemic attack, or clinically significant cardiac arrhythmias within 6 months prior to screening, or a previous diagnosis of decompensated heart failure or New York Heart Association (NYHA) grade III or IV heart failure. Other protocol-defined inclusion/exclusion criteria may apply